Cancer Therapy News and Research

RSS

Advancements in antibody-drug conjugates transform cancer therapy

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs.

22 Oct 2024

Cutting off cancer cells' access to fats may enhance cancer therapy

Cutting off cancer cells' access to fat may help a specific type of cancer treatment work more effectively, reports a study by Van Andel Institute scientists.

22 Oct 2024

Breakthrough discovery of selective MMP7 inhibitor offers hope for cancer treatment

A team of researchers from the Hebrew University of Jerusalem, the Weizmann Institute of Science, and the University of Tokyo has made a significant breakthrough in the fight against cancer by developing a highly selective inhibitor for an enzyme called Matrix Metallopeptidase 7 (MMP7).

18 Oct 2024

ALS drug shows promise in targeting glioblastoma stem cells

Glioblastoma is the most common – and the most malignant – primary brain tumor in adults. It's aggressive and incurable.

17 Oct 2024

New compounds from fungi show promise in treating colorectal cancer

Novel chemical compounds from a fungus could provide new perspectives for treating colorectal cancer, one of the most common and deadliest cancers worldwide.

17 Oct 2024

NYU Langone researchers address the challenges of heart failure in cancer patients

A new scientific statement issued today by the Heart Failure Society of America highlights a critical connection between heart failure (HF) and cancer, with shared mechanisms contributing to the incidence and progression of both diseases.

16 Oct 2024

Distinct immune profiles linked to adverse reactions from immunotherapy

Distinct immune "signatures" in patients who develop adverse events while taking immunotherapy for cancer may help oncologists identify patients at risk and treat them early to prevent serious side effects, suggests a study by researchers from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

15 Oct 2024

Innovative bacteria-based therapy shows promise against cancer

Even as cancer remains a leading cause of death globally, bacteria-based cancer therapy presents an exciting and innovative treatment option.

15 Oct 2024

Common breast cancer therapies may speed up aging, study shows

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center has revealed that common breast cancer treatments, including chemotherapy, radiation, and surgery, may accelerate the biological aging process in breast cancer survivors.

8 Oct 2024

Jefferson Lab team explores proton therapy as a safer cancer treatment

Radiation therapy techniques have been used for more than a century to treat cancers. Physicists in the Radiation Detector and Imaging group and associated with the Biomedical Research & Innovation Center (BRIC) at the U.S. Department of Energy's Thomas Jefferson National Accelerator Facility have been for several years pursuing radiation therapy technology improvements in collaboration with the Hampton University Proton Cancer Institute (HUPCI).

4 Oct 2024

New insights into the role of gamma-delta T cells across 33 cancer types revealed

A new study published in Cell Press reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic targets in cancer treatment.

4 Oct 2024

Traditional Chinese medicine shows potential in cancer treatment

Cancer, a pervasive global health concern, remains a leading cause of mortality worldwide. Current cancer treatment modalities encompass surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy, all of which have significantly contributed to improving patient survival.

1 Oct 2024

Optimized nanoadjuvants enhance in situ tumor vaccine for ovarian cancer

This new article publication from Acta Pharmaceutica Sinica B, discusses how molecular glue triggers degradation of PHGDH by enhancing the interaction between DDB1 and PHGDH.

25 Sep 2024

Sexual health symptoms associated with lower adherence to breast cancer therapy in Black women

Among patients with early-stage breast cancer treated with adjuvant endocrine therapy (AET), symptoms related to sexual health were associated with decreased adherence to treatment in Black women, according to results presented at the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held September 21-24, 2024.

21 Sep 2024

ESMO Congress 2024 to unveil future-focused cancer treatments

The ESMO Congress 2024 will hold a press conference to introduce and discuss the "Eyes to the Future" Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.

16 Sep 2024

New cancer drug shows encouraging results in Phase I/II trial

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.

14 Sep 2024

PPARs and PROTACs: A new strategy in cancer therapeutics

The growing challenge in cancer therapy lies in overcoming tumor heterogeneity, drug resistance, and associated side effects.

13 Sep 2024

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma, a form of kidney cancer.

13 Sep 2024

Advances in targeting the CD47/SIRPα "do not eat me" pathway for cancer therapy

A new editorial was recently published in Oncotarget's Volume 15, on July 10, 2024, entitled, "The advances in targeting CD47/SIRPα "do not eat me" axis and their ongoing challenges as an anticancer therapy."

13 Sep 2024

Researchers uncover why typically normal protein drives prostate cancer

NSD-2 is crucial for AR activity in prostate cancer, promoting tumor growth and offering a potential therapeutic target for advanced prostate cancer treatment.

12 Sep 2024